Eigen Therapeutics is developing a platform that primes cancer cells to raise levels of proteins targeted by immunotherapies and antibody treatments, broadening the range of susceptible tumor cells. The company positions itself to address precision and specificity gaps in conventional cancer therapies, including resistance, rapid cancer cell evolution, and the complex tumor microenvironment. Eigen pairs its biology with an automated lab infrastructure and high-throughput screening to accelerate discovery and scale experimentation. Its approach is intended to enhance the effectiveness of existing therapies and make advanced, tailored treatments accessible to more patients. Leadership includes CEO and Co‑Founder Transon Nguyen, CTO and Co‑Founder Kamran Ali, and Chief Scientific Officer Kathryn Vanderlaag. The company reports significant milestones since December 2022 and cites a growing precision oncology medicines market as supporting demand for its work. Eigen Therapeutics builds priming therapies that increase target expression across cancer cells to make them more recognizable and vulnerable to targeted therapeutics. The company uses a proprietary high-throughput platform combining combinatorial functional screening, in-house robotics, laboratory operations software, and machine-learning analysis to discover agents that change a cell's state. Initial programs are focused on hematological malignancies, with plans to quickly spin up programs for other indications including solid tumors. Founders Transon Nguyen and Kamran Ali are veterans of Notable Labs and have assembled a team of technology and biological-science experts. Eigen launched from stealth in Redwood City, Calif., was founded in September 2021, and announced a $7 million seed round. The company says it will use the seed capital to apply its platform toward the development of priming therapies.

Total raised

$7M

Funding rounds

2

Latest round

Seed

Latest activity

Dec 2022